Spyryx Biosciences: About Us

Spyryx Biosciences is pioneering the use of inhaled peptides to treat severe pulmonary diseases where mucus accumulation and obstructions are key to disease progression. Our compounds have a novel mechanism of action that removes epithelial sodium channels from the airway surface with the therapeutic goal of increasing airway hydration and mucus clearance to enhance lung performance. Spyryx’s lead program, SPX-101, is in Phase 2 testing for CF.

Please Note: The Spyryx Biosciences website uses cookies. Cookies are text files placed on your computer to collect standard Internet log information and visitor behavior information. Spyryx uses cookies in a range of ways to improve your experience on our website. Our number one use is for functionally so you can be on the site and navigate to pages with ease. We also use cookies to understand how people use our website, content viewed, links followed, etc. We do not use cookies for marketing purposes and we never share data with third parties. You can set your browser to not accept cookies and in a few cases, some of our website features may not function as a result.